---
title: "NVCT.US (NVCT.US) — Related News"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/NVCT.US/news.md"
symbol: "NVCT.US"
name: "NVCT.US"
parent: "https://longbridge.com/en/quote/NVCT.US.md"
datetime: "2026-03-09T07:10:38.748Z"
locales:
  - [en](https://longbridge.com/en/quote/NVCT.US/news.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/NVCT.US/news.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/NVCT.US/news.md)
---

> Supported Languages: [简体中文](https://longbridge.com/zh-CN/quote/NVCT.US/news.md) | [繁體中文](https://longbridge.com/zh-HK/quote/NVCT.US/news.md)


# NVCT.US (NVCT.US) — Related News

### [Biotech Stocks Facing FDA Decision In March 2026](https://longbridge.com/en/news/276853614.md)
*2026-02-25T08:10:40.000Z*
> Biotech stocks are awaiting FDA decisions in March 2026 for New Drug Applications including Reproxalap, Linerixibat, Kre

### [Nuvectis Pharma Inc. FY25 net loss attributable to common shareholders widens to USD 28.87 million, up 52%](https://longbridge.com/en/news/275605173.md)
*2026-02-11T12:32:47.000Z*
> Nuvectis Pharma Inc. reported a widened net loss of USD 28.87 million for FY25, a 52% increase. Research and development

### [Positive Recommendation on Nuvectis Pharma Driven by Promising Lead Candidate and Milestone Clinical Studies](https://longbridge.com/en/news/270032681.md)
*2025-12-17T15:05:20.000Z*
> Analyst Joseph Pantginis from H.C. Wainwright reiterated a Buy rating for Nuvectis Pharma, with a $10.00 price target. T

### [Nuvectis Pharma Launches Phase 1b Trial of NXP900 and Osimertinib in EGFRmut+ NSCLC](https://longbridge.com/en/news/270006176.md)
*2025-12-17T12:00:26.000Z*
> Nuvectis Pharma Inc. has initiated a Phase 1b clinical trial to evaluate the combination of NXP900 and osimertinib in EG

### [Nuvectis Pharma Hosts Virtual Meeting on NXP900 Phase 1b Program in Advanced Solid Tumors](https://longbridge.com/en/news/267359156.md)
*2025-11-25T13:00:24.000Z*
> Nuvectis Pharma Inc. will host a virtual meeting on December 2, 2025, to discuss the NXP900 Phase 1b Program in advanced

### [Buy Rating for Nuvectis Pharma’s NXP900 Driven by Promising Efficacy and Development Progress](https://longbridge.com/en/news/266418541.md)
*2025-11-18T16:55:25.000Z*
> Naz Rahman from Maxim Group maintains a Buy rating on Nuvectis Pharma with a $17.00 price target, driven by the promisin

### [Nuvectis Pharma Executives Make Bold Moves with Major Stock Purchases!](https://longbridge.com/en/news/264767402.md)
*2025-11-07T02:07:44.000Z*
> Nuvectis Pharma executives made significant stock purchases on November 6, 2025, with Chairman & CEO Ron Bentsur buying 

### [Nuvectis Pharma FY2029 EPS Forecast Lifted by Roth Capital](https://longbridge.com/en/news/264677828.md)
*2025-11-06T14:16:46.000Z*
> Roth Capital has raised its FY2029 earnings forecast for Nuvectis Pharma (NASDAQ: NVCT) from $3.10 to $3.34 per share. T